Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?
Garrido-Laguna
Ignacio
I
Ponz
Mariano
M
Espinós
Jaime
J
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D003627:Data Interpretation, Statistical; D005121:Extremities; D006801:Humans; D006979:Hyperthermia, Induced; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan